The board of directors of Nasdaq-listed company Anixa Biosciences has approved the purchase of Bitcoin as a reserve asset
According to PR Newswire, Anixa Biosciences, Inc. (NASDAQ: ANIX), a Nasdaq-listed company in the United States, announced that its board of directors has approved the purchase of Bitcoin as a treasury reserve asset with the aim of diversifying the company's assets and enabling Anixa to benefit from the potential long-term value of digital assets. It is reported that Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ledger: currently manages about 20% of the world's crypto assets, worth about $400 billion
An address holding 965,000 DOGEs was activated after 10.9 years of dormancy.
An address holding 965,000 DOGEs was activated after 10.9 years of dormancy.
Bitget is now live on the U-native MEMEFI perpetual contract